China Journal of Oral and Maxillofacial Surgery ›› 2019, Vol. 17 ›› Issue (4): 316-318.doi: 10.19438/j.cjoms.2019.04.006

• Orginal Article • Previous Articles     Next Articles

The effects of preemptive analgesia with nalbuphine on postoperative pain in elder patients undergoing surgery of oral and maxillofacial neoplasms

ZHU Hao-zhen, SUN Yu   

  1. Department of Anesthesiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011, China
  • Received:2019-01-21 Revised:2019-03-21 Online:2019-07-20 Published:2019-08-12

Abstract: PURPOSE: The purpose of this study was to evaluate the effects of preemptive single dose nalbuphine on postoperative pain in elder patients undergoing surgery of oral and maxillofacial neoplasms. Methods: The study enrolled 100 tumour patients aged 61 to 84 undergoing oral and maxillofacial surgery. The patients were randomly divided into 2 groups: nalbuphine group (group N, n=51), receiving 20 mg nalbuphine before surgery; while patients in the control group (group C, n=49) received 2 mL normal saline. Patients in both groups underwent same general anesthesia protocol. Postoperative analgesia was assessed by using visual analogue scale (VAS) 1, 2, 6, 12 and 24 h after surgery. The incidence of adverse reactions and additional analgesia consumption were recorded. The data were statistically analyzed with SPSS 22.0 software package. Results: VAS scores in nalbuphine group were significantly lower than the control group 6, 12, 24 h after surgery (P<0.05). 24-hour additional analgesia consumption was significantly smaller in the nalbuphine group than in the control group (P<0.05). The ratio of adverse reaction was significantly lower in nalbuphine group than in the control group (P<0.05). Conclusions: Preemptive analgesia with nalbuphine reduced postoperative VAS scores, adverse event and additional analgesia consumption in elder patients undergoing surgery of oral and maxillofacial neoplasms.

Key words: Nalbuphine, Preemptive analgesia, Oral and maxillofacial neoplasms

CLC Number: